57381-26-7
57381-26-7 structure
- Name: Irsogladine
- Chemical Name: Irsogladine
- CAS Number: 57381-26-7
- Molecular Formula: C9H7Cl2N5
- Molecular Weight: 256.091
- Catalog: API Digestive system medication Acid and gastric mucosal protective drugs
- Create Date: 2018-07-01 11:07:10
- Modify Date: 2024-01-02 20:25:30
-
Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.Target: PDE4; mACHRIrsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].
| Name | Irsogladine |
|---|---|
| Synonyms |
2',5'-Dichlorobenzoguanamine
1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- MFCD00866871 Irsogladin 6-(2,5-Dichlorophenyl)-1,3,5-triazine-2,4-diamine gaslon Irsogladine Dicloguamine |
| Description | Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.Target: PDE4; mACHRIrsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 552.2±60.0 °C at 760 mmHg |
| Melting Point | 268-269°C |
| Molecular Formula | C9H7Cl2N5 |
| Molecular Weight | 256.091 |
| Flash Point | 287.8±32.9 °C |
| Exact Mass | 255.007858 |
| PSA | 90.71000 |
| LogP | 2.08 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.706 |
| Storage condition | -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Hazard Codes | Xn,N |
|---|---|
| Risk Phrases | R20:Harmful by inhalation. R51/53:Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment . |
| Safety Phrases | S24-S61 |
| RIDADR | UN 2618 3/PG 3 |
| WGK Germany | 2 |
| RTECS | WL5075900 |
| Packaging Group | III |
| Hazard Class | 3 |
| HS Code | 2942000000 |
| HS Code | 2942000000 |
|---|